IAA Journal of Scientific Research 13(1):102-110, 2026. www.iaajournals.org



ISSN: 2636-7319

https://doi.org/10.59298/IAAJSR/2026/131102110 IAAJSR:1311

# Engineering Nanoparticles to Modulate Gut Microbiota in Obesity-Induced Insulin Resistance

**Muhindo Anitah**

**Department of Pharmacy Kampala International University Uganda**
**Email: anitah.muhindo@studwc.kiu.ac.ug**

## ABSTRACT

Obesity-induced insulin resistance emerges from intertwined host–microbe interactions that reshape intestinal permeability, immune tone, and metabolic signaling. Dysbiosis, characterized by reduced microbial diversity, altered short-chain fatty acid production, perturbed bile acid pools, and increased endotoxin translocation, amplifies systemic inflammation and impairs insulin action. Conventional approaches—dietary fiber, probiotics, and antibiotics often show variable efficacy due to poor colon targeting, instability across the gastrointestinal tract, off-target effects, and person-to-person microbiome heterogeneity. Engineered nanoparticles offer a precision toolkit to tune the gut ecosystem and its crosstalk with the host. By co-optimizing materials, size, surface chemistry, and stimuli-responsive release, nanoparticles can protect labile cargos, navigate mucus and epithelial barriers, selectively deliver prebiotics, postbiotics, enzymes, microbial modulators, or gene editors to specific niches, and even sequester luminal toxins such as lipopolysaccharide. This review articulates design principles for gut-directed nanocarriers; examines strategies to enrich beneficial taxa and functions, attenuate pathobionts, and restore barrier integrity; and outlines theranostic systems that couple localized imaging with microbiota-targeted therapy. We evaluate safety, manufacturability, and regulatory considerations, and propose clinical trial frameworks integrating multi-omics, breath and plasma metabolomics, and continuous glucose monitoring. By aligning materials science with microbial ecology, nanoparticle platforms can convert microbiome modulation from broad-stroke interventions into targeted, durable, and metabolically meaningful therapy.

**Keywords:** gut microbiota; nanoparticles; dysbiosis; insulin resistance; obesity; short-chain fatty acids; bile acids; endotoxemia; mucus-penetrating particles; oral nanomedicine

## INTRODUCTION

The gut microbiota orchestrates a substantial portion of human metabolic homeostasis through fermentation of dietary substrates, production of signaling metabolites, modulation of bile acid transformations, and education of the mucosal immune system[1–4]. In obesity, this ecosystem often shifts toward reduced diversity, enrichment of pathobionts, and altered functional profiles that collectively impair host insulin signaling. Mechanistically, a decrease in butyrate-producing taxa lowers epithelial energy sources and tight junction support, while increased lipopolysaccharide from Gram-negative organisms drives metabolic endotoxemia[5–7]. Bile acid pools tilt toward species that less robustly activate farnesoid X receptor and TGR5, blunting beneficial effects on glucose and lipid metabolism. Concomitantly, low-grade inflammation arising from barrier disruption and innate immune activation propagates hepatic and adipose insulin resistance[8–10].

Standard interventions target this axis with varying success. Diets enriched in fermentable fibers can increase short-chain fatty acid output and improve insulin sensitivity, but adherence and interindividual responses limit consistency [11-17]. Probiotics and live biotherapeutics deliver selected strains, yet gastric acid, bile, and competition within complex communities hinder colonization, and single strains rarely shift ecosystem-level function[18-24]. Non-absorbable antibiotics reduce microbial load but risk collateral damage, resistance, and rebound dysbiosis. Fecal microbiota transplantation demonstrates the power of wholesale ecosystem replacement, yet donor selection, durability, and regulatory hurdles remain formidable [18-19].

Nanotechnology enables a middle path between blunt and bespoke approaches. Oral nanoparticles can shield cargo from gastric acidity and proteases, navigate the viscoelastic mucus layer, and release payloads in response to pH, enzymatic activity, or redox gradients specific to the lower intestine[20-26]. Surface grafts with polyethylene glycol alternatives or zwitterionic brushes reduce mucoadhesion enough to penetrate mucus, while a second, inner layer confers site-specific adhesion to epithelium or bacterial surfaces once deeply embedded in the mucus mesh. Enteric coatings ensure delivery past the stomach, and lipid-rich or bile-mimetic compositions can bias uptake into lymphatics when host targeting is desired. Critically, modular architectures support combination therapy: the same particle can carry a prebiotic oligosaccharide, a bacteriophage or CRISPR–antimicrobial construct against a pathobiont, and a postbiotic such as butyrate or secondary bile acid analog, each with orthogonal release triggers[27-30].

Host-directed effects are equally important. Nanoparticles decorated with tight junction–stabilizing peptides, antioxidant thioketals, or TLR4 antagonists can restore barrier integrity and dampen mucosal inflammation, thereby reducing the inflammatory drive on systemic insulin resistance[31-35]. Other designs sequester luminal toxins, adsorbing lipopolysaccharide, bacterial quorum-sensing molecules, or excess bile acids, to blunt pathogenic signaling while allowing commensal functions to recover. Diagnostic elements integrated into the same platforms, including near-infrared dyes or photoacoustic reporters, can map regional accumulation and microenvironmental cues, creating theranostic feedback loops that personalize dosing[36-39].

Translation requires that these elegant designs perform under the messy realities of diet, motility differences, and microbial variability. Materials must be safe for chronic ingestion, manufacturable at scale, and compatible with re-dosing without altering the microbiome in unintended ways[40-45]. Clinically meaningful endpoints must extend beyond fasting glucose to include continuous glucose monitoring metrics, insulin sensitivity indices, liver fat content, and inflammatory markers, ideally linked to metagenomic and metabolomic shifts that demonstrate mechanistic action[46-50]. As incretin-based therapies and SGLT2 inhibitors become widespread, microbiome-directed nanoparticles can complement these agents by restoring the epithelial and immune tone that underpins durable insulin sensitivity. This review synthesizes the principles and practices of engineering nanoparticles to modulate the gut microbiota in obesity-induced insulin resistance, with emphasis on rational design, functional targeting, safety, and pathways to clinical adoption.

## 2. Rebuilding Beneficial Functions: Prebiotics, Postbiotics, and Engineered Consortia

Restoring metabolic resilience often requires boosting fermentative capacity and the production of health-promoting metabolites without relying solely on colonization by exogenous strains[51]. Nanoparticles can deliver prebiotic oligosaccharides, arabinoxylans, inulins, and resistant starch fragments in protected forms that resist small-intestine digestion and concentrate in the colon. Encapsulation reduces bloating by modulating fermentation rate and spatial distribution, encouraging gradual production of short-chain fatty acids that sustain epithelial energy and regulatory T cell differentiation[51-56]. Co-delivery with trace minerals or cofactors can support microbial cross-feeding networks that maintain butyrate pools.

Postbiotics bypass colonization uncertainty. Butyrate or propionate can be released from prodrugs or nanoparticle cores in a colon-restricted manner, avoiding upper-GI absorption and unpleasant taste or odor[57-60]. Smart linkers that respond to bacterial enzymes ensure that release scales with microbial activity, creating a feedback alignment between supply and demand. Bile acid modulators can be similarly localized: nanoparticles carrying bile salt hydrolase enzymes, selective inhibitors of 7α-dehydroxylation, or mimetics that activate TGR5 can reshape bile pools toward insulin-sensitizing profiles while limiting systemic exposure.

Engineered consortia benefit from nano-enabled shelter and communication. Protective microgels seeded with rationally designed commensals provide a microenvironment that mitigates initial competitive disadvantage, slowly releasing organisms into biofilms where they can persist[61-65]. Nanoparticles delivering quorum-sensing agonists or antagonists can tilt interspecies signaling, promoting beneficial taxa while suppressing virulence gene expression in pathobionts. When live organisms are not preferred, bacterial extracellular vesicles or purified cell wall components loaded into nanoparticles can recapitulate immunomodulatory effects without colonization.

Host–microbe signaling is a critical endpoint. Nanocarrier-enhanced SCFA delivery increases GPR41/43 signaling in enteroendocrine cells, elevating peptide YY and GLP-1 in a glucose-dependent fashion, which in turn improves insulin sensitivity and satiety[66-70]. Locally increased butyrate strengthens histone acetylation in colonocytes and tight junction gene expression, reinforcing barrier integrity. By calibrating where and how fast these signals are generated, nanoparticles convert blunt prebiotic strategies into predictable, titratable interventions that support durable metabolic improvements.

## 3. Subtracting Harmful Drivers: Targeted Depletion, Phage/CRISPR Strategies, and Toxin Sequestration

Dysbiosis is not only the absence of good; it is the presence of harmful functions. Targeted subtraction reduces pathobionts or their virulence traits without wholesale ecosystem disruption[71-75]. Bacteriophage-loaded nanoparticles protect phage from acid and bile, extend their reach through mucus, and co-deliver adjuvants that suppress CRISPR-Cas anti-phage defenses in target bacteria. Phage can be tuned to narrow host ranges, sparing commensals and enabling precise debulking of endotoxin-rich lineages. CRISPR–antimicrobial particles that carry guide RNAs and Cas effectors within protective shells can selectively silence antibiotic resista.nce genes or virulence factors, attenuating pathogenicity while allowing ecological coexistence [76-80]

Small-molecule quorum-sensing inhibitors encapsulated for colon release blunt coordinated behaviors like biofilm fortification or toxin production. When quorum circuits are dampened, pathobionts become less competitive, allowing beneficial taxa to reclaim niches. Nanoparticles that bind and neutralize luminal toxins offer an orthogonal strategy[81-84]. Hydrophobic and cationic domains can adsorb lipopolysaccharide, while boronic-acid–functionalized surfaces capture furanones and other signaling molecules. Activated-carbon nanocomposites with controlled pore sizes concentrate sequestration in the colon and avoid micronutrient depletion sometimes seen with systemic binders.

Antibiotics retain a role but benefit from localization. Delivering microdoses of non-absorbed antibiotics or antimicrobial peptides in colon-restricted, time-limited pulses minimizes collateral damage and resistance selection[85-88]. Enzyme-responsive gates ensure that release coincides with blooms of target organisms, detected indirectly by elevated azoreductase activity or directly via diagnostic signals embedded in the platform. After subtraction, supportive cargos postbiotics or prebiotics help stabilize the new equilibrium and guard against rebound dysbiosis[89-92].

Safety is paramount. Off-target editing, horizontal gene transfer, and phage immunogenicity must be monitored[93-94]. Materials should avoid provoking mucosal inflammation or altering epithelial turnover. By pairing narrow-acting depletion tools with stabilization strategies, nanoparticles can subtract harmful drivers of metabolic endotoxemia and inflammation while preserving the complexity needed for resilient, insulin-sensitizing ecosystems.

**4. Restoring the Barrier and Immune Tone: Epithelial Repair and Mucosal Immunomodulation**

The intestinal barrier is both physical and immunological. In obesity, tight junction disassembly, altered mucus composition, and skewed innate and adaptive responses increase permeability to microbial products that seed systemic inflammation and insulin resistance[95-99]. Nanoparticles can restore this barrier by delivering epithelial trophic factors, epidermal growth factor fragments, trefoil peptides, or Wnt agonists in colon-selective formulations that avoid systemic mitogenic exposure. Butyrate-releasing particles complement this by fueling colonocytes and upregulating claudins and occludin, whereas thioketal-containing polymers scavenge reactive oxygen species that destabilize junctional complexes[100-103].

Immunomodulatory cargos refine tone without systemic immunosuppression. Nanoparticles that present tolerogenic motifs or deliver NF-κB inhibitors locally can reduce proinflammatory cytokines from lamina propria macrophages and dendritic cells[104-106]. Oral delivery of encapsulated low-dose antigens combined with rapamycin or retinoic acid establishes regulatory T cell responses that generalize to dampen excessive reactions to commensals. For innate pathways, TLR4 antagonists or IRAK4 inhibitors confined to the mucosa prevent endotoxin amplification loops while sparing systemic host defense[107-108].

Mucin dynamics matter. Particles that enhance goblet cell function through localized growth factor delivery or that supply sialylated glycans can thicken and normalize mucus architecture, reestablishing a habitat that favors commensal colonization and reduces epithelial contact with pathobionts[109]. Conversely, excessive mucoadhesion by therapeutic particles is undesirable; switchable coatings ensure that adhesion is a transient step toward productive delivery rather than persistent clogging that alters mucus turnover[110].

These barrier and immune interventions translate into systemic benefit by reducing portal endotoxin load, hepatic Kupffer cell activation, and adipose tissue macrophage recruitment. The downstream result is improved hepatic insulin signaling, reduced adipose inflammation, and better skeletal muscle glucose uptake[111]. By rebuilding the barrier and recalibrating immune tone in situ, nanoparticles address a root cause of obesity-induced insulin resistance rather than exclusively treating downstream glycemia.

**5. Theranostic Platforms: Imaging-Guided Microbiota Modulation and Adaptive Dosing**

Heterogeneity in microbiome composition and host physiology demands feedback to personalize therapy. Theranostic nanoparticles co-embed imaging reporters with therapeutic cargos to visualize distribution, dwell time, and microenvironmental triggers[48]. Near-infrared fluorophores or photoacoustic dyes tethered to responsive linkers brighten upon enzymatic cleavage by bacterial azoreductases, providing a noninvasive readout of colon activation that correlates with payload release[48]. Magnetic resonance–visible particles with embedded paramagnetic agents can map colonic regions with altered permeability or inflammation, while radiolabeled tracers at microdose levels quantify whole-gut transit and regional retention.

These readouts underpin adaptive dosing. If a patient's baseline scan shows rapid transit and limited colonic activation, formulations can be adjusted toward higher muco-penetration or delayed-release thresholds. Conversely, prolonged retention may justify lower doses to avoid accumulation. Coupling theranostic signals with stool metagenomics and metabolomics allows attribution of response to specific taxa or pathways such as restoration of butyrogenic clusters or normalization of bile acid ratios, tightening the loop between mechanism and outcome[49].

External triggers add another layer of control. Low-intensity focused ultrasound can transiently enhance the permeability of responsive coatings, synchronizing release with meals to blunt postprandial glycemic excursions[50, 51]. Light-activated systems applied via ingestible devices can trigger regional pulses in the colon. These approaches pair with continuous glucose monitoring to measure functional impact in real time, enabling within-person dose titration without extensive clinic visits.

Regulatory and practical considerations guide design. Imaging components must operate safely at doses compatible with chronic use, and theranostic data should translate into pre-specified decision rules rather than ad hoc interpretation. When implemented thoughtfully, theranostic nanoparticles convert microbiota modulation from a black box into an observable, optimizable process that respects the diversity of human gut ecosystems.

**6. Translation, Safety, and Clinical Trial Design for Microbiome-Targeted Nanotherapies**

Clinical development should match platform intent with endpoints that matter to people living with obesity and insulin resistance. Early-phase studies emphasize safety, tolerability, and pharmacodynamics using multi-omics and imaging. Stool metagenomics and metatranscriptomics quantify community shifts; targeted and untargeted metabolomics track short-chain fatty acids, bile acids, and microbial-derived aromatic compounds; breath tests measure hydrogen and methane as fermentation surrogates; and plasma assays capture endotoxin activity and inflammatory mediators[52]. Continuous glucose monitoring and meal-tolerance tests assess metabolic impact alongside HOMA-IR or clamp-derived insulin sensitivity in selected cohorts[52].

Safety considerations reflect chronic, luminal exposure. Materials should be non-cytotoxic to epithelium, non-accumulative, and free of heavy metals or leachable monomers. For phage or CRISPR cargos, shedding, off-target effects, and horizontal gene transfer require surveillance[21, 22, 35]. Antibiotic-resistance selection must be minimized through narrow targeting and short pulse exposures. Immunogenicity is addressed by mucosa-confined delivery and avoidance of strongly adjuvanting motifs unless purposefully tolerogenic. Manufacturing under GMP demands tight control of particle size, polydispersity, residual solvent, microbial bioburden, and batch consistency in release profiles; for live cargos, viability and plasmid stability become critical quality attributes.

Trial design benefits from enrichment strategies. Baseline microbiome and metabolome phenotypes can identify likely responders, such as individuals with depleted butyrate producers or high secondary bile acid signatures[12, 53, 54]. Randomized, placebo-controlled designs should incorporate diet standardization periods to reduce confounding. Pragmatic features, such as home stool collection, remote CGM uploads, and digital symptom diaries, enhance feasibility. Clinically meaningful goals include increased time in glucose range, reductions in glycemic variability and hepatic fat, and improvements in patient-reported outcomes like gastrointestinal comfort and treatment burden.

Positioning within care pathways is essential. Nanoparticle microbiome modulators may serve as adjuncts to lifestyle and pharmacotherapy, potentially lowering doses of incretins and improving tolerability[23, 48, 55]. Health-economic analyses should capture reduced medication use, fewer hypoglycemic episodes, and improvements in fatty liver indices. If platforms demonstrate durable metabolic benefit with favorable safety and usability, they can expand the toolkit for addressing insulin resistance at its mucosal roots.

## CONCLUSIONS

Obesity-induced insulin resistance is inseparable from disturbances at the intestinal interface, where microbes, metabolites, and the mucosal immune system shape systemic metabolism. Engineering nanoparticles for gut delivery provides a means to restore this interface with precision: protecting and placing cargos exactly where they act, subtracting harmful functions while rebuilding beneficial ones, repairing the barrier, and calibrating immune tone. By layering targeting ligands, stimuli-responsive chemistries, and theranostic readouts, these platforms transform microbiome modulation into a controllable therapy aligned with individual ecology and physiology. Translation will depend on food-safe materials, scalable manufacturing, rigorous safety, and trials that marry multi-omics with continuous glucose monitoring and organ-level imaging. As part of an integrated strategy alongside diet, exercise, and contemporary metabolic drugs, gut-directed nanoparticles can move care upstream—treating causes rather than consequences—and deliver durable gains in insulin sensitivity and metabolic health.

## REFERENCES

1. Archana, Gupta, A.K., Noumani, A., Panday, D.K., Zaidi, F., Sahu, G.K., Joshi, G., Yadav, M., Borah, S.J., Susmitha, V., Mohan, A., Kumar, A., Solanki, P.R.: Gut microbiota derived short-chain fatty acids in physiology and pathology: An update. Cell Biochem. Funct. 42, e4108 (2024). https://doi.org/10.1002/cbf.4108
2. Bajinka, O., Tan, Y., Darboe, A., Ighaede-Edwards, I.G., Abdelhalim, K.A.: The gut microbiota pathway mechanisms of diabetes. AMB Express. 13, 16 (2023). https://doi.org/10.1186/s13568-023-01520-3
3. Ugwu, O.P.-C., Okon, M.B., Alum, E.U., Ugwu, C.N., Anyanwu, E.G., Mariam, B., Ogenyi, F.C., Eze, V.H.U., Anyanwu, C.N., Ezeonwumelu, J.O.C., Egba, S.I., Uti, D.E., Onohuean, H., Aja, P.M., Ugwu, M.N.: Unveiling the therapeutic potential of the gut microbiota–brain axis: Novel insights and clinical applications in neurological disorders. Medicine (Baltimore). 104, e43542 (2025). https://doi.org/10.1097/MD.0000000000043542
4. Alum, E.U., Uti, D.E., Ugwu, O.P.-C., Alum, B.N., Edeh, F.O., Ainebyoona, C.: Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment. Discov. Oncol. 16, 646 (2025). https://doi.org/10.1007/s12672-025-02352-2
5. González-Gómez, Á., Cantone, M., García-Muñoz, A.M., Victoria-Montesinos, D., Lucas-Abellán, C., Serrano-Martínez, A., Muñoz-Morillas, A.M., Morillas-Ruiz, J.M.: Effect of Polyphenol-Rich Interventions on Gut Microbiota and Inflammatory or Oxidative Stress Markers in Adults Who Are Overweight or Obese: A Systematic Review and Meta-Analysis. Nutrients. 17, 2468 (2025). https://doi.org/10.3390/nu17152468

6. Leeming, E.R., Johnson, A.J., Spector, T.D., Le Roy, C.I.: Effect of Diet on the Gut Microbiota: Rethinking Intervention Duration. Nutrients. 11, 2862 (2019). https://doi.org/10.3390/nu11122862
7. Kardan, R., Hemmati, J., Nazari, M., Ahmadi, A., Asghari, B., Azizi, M., Khaledi, M., Arabestani, M.R.: Novel therapeutic strategy for obesity through the gut microbiota-brain axis: A review article. Casp. J. Intern. Med. 15, 215–227 (2024). https://doi.org/10.22088/cjim.15.2.215
8. Kim, J.-Y., Lee, Y.-S., Park, E.-J., Lee, H.-J.: Honeysuckle Berry (Lonicera caerulea L.) Inhibits Lipase Activity and Modulates the Gut Microbiota in High-Fat Diet-Fed Mice. Molecules. 27, 4731 (2022). https://doi.org/10.3390/molecules27154731
9. Larabi, A.B., Masson, H.L.P., Bäumler, A.J.: Bile acids as modulators of gut microbiota composition and function. Gut Microbes. 15, 2172671. https://doi.org/10.1080/19490976.2023.2172671
10. Fusco, W., Lorenzo, M.B., Cintoni, M., Porcari, S., Rinninella, E., Kaitsas, F., Lener, E., Mele, M.C., Gasbarrini, A., Collado, M.C., Cammarota, G., Ianiro, G.: Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota. Nutrients. 15, 2211 (2023). https://doi.org/10.3390/nu15092211
11. Alum, E.U., Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
12. Hills, R.D., Pontefract, B.A., Mishcon, H.R., Black, C.A., Sutton, S.C., Theberge, C.R.: Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 11, 1613 (2019). https://doi.org/10.3390/nu11071613
13. Holmes, Z.C., Villa, M.M., Durand, H.K., Jiang, S., Dallow, E.P., Petrone, B.L., Silverman, J.D., Lin, P.-H., David, L.A.: Microbiota responses to different prebiotics are conserved within individuals and associated with habitual fiber intake. Microbiome. 10, 114 (2022). https://doi.org/10.1186/s40168-022-01307-x
14. Ugwu, O.P.-C., Alum, E.U., Okon, M.B., Obeagu, E.I.: Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. Medicine (Baltimore). 103, e38088 (2024). https://doi.org/10.1097/MD.0000000000038088
15. Al Tahan, M.A., Al-Khattawi, A., Russell, C.: Oral peptide delivery Systems: Synergistic approaches using polymers, lipids, Nanotechnology, and needle-based carriers. J. Drug Deliv. Sci. Technol. 112, 107205 (2025). https://doi.org/10.1016/j.jddst.2025.107205
16. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J. Pers. Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
17. Awlqadr, F.H., Majeed, K.R., Altemimi, A.B., Hassan, A.M., Qadir, S.A., Saeed, M.N., Faraj, A.M., Salih, T.H., Abd Al-Manhel, A.J., Najm, M.A.A., Tsakali, E., Van Impe, J.F.M., Abd El-Maksoud, A.A., Abedelmaksoud, T.G.: Nanotechnology-based herbal medicine: Preparation, synthesis, and applications in food and medicine. J. Agric. Food Res. 19, 101661 (2025). https://doi.org/10.1016/j.jafr.2025.101661
18. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
19. Aljabali, A.A.A., El-Tanani, M., Tambuwala, M.M.: Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery. J. Drug Deliv. Sci. Technol. 92, 105338 (2024). https://doi.org/10.1016/j.jddst.2024.105338
20. Ansori, A.NM., Antonius, Y., Susilo, R.JK., Hayaza, S., Kharisma, V.D., Parikesit, A.A., Zainul, R., Jakhmola, V., Saklani, T., Rebezov, M., Ullah, Md.E., Maksimiuk, N., Derkho, M., Burkov, P.: Application of CRISPR-Cas9 genome editing technology in various fields: A review. Narra J. 3, e184 (2023). https://doi.org/10.52225/narra.v3i2.184
21. Chen, T., Barzi, M., Furey, N., Kim, H.R., Pankowicz, F.P., Legras, X., Elsea, S.H., Hurley, A.E., Yang, D., Wheeler, D.A., Borowiak, M., Bissig-Choisat, B., Sumazin, P., Bissig, K.-D.: CRISPR/Cas9 gene therapy increases the risk of tumorigenesis in the mouse model of hereditary tyrosinemia type I. JHEP Rep. 7, 101327 (2025). https://doi.org/10.1016/j.jhepr.2025.101327
22. Dara, M., Dianatpour, M., Azarpira, N., Tanideh, N., Tanideh, R.: Integrating CRISPR technology with exosomes: Revolutionizing gene delivery systems. Biochem. Biophys. Res. Commun. 740, 151002 (2024). https://doi.org/10.1016/j.bbrc.2024.151002
23. Zhou, S., Deng, H., Zhang, Y., Wu, P., He, B., Dai, W., Zhang, H., Zhang, Q., Zhao, R., Wang, X.: Thiolated Nanoparticles Overcome the Mucus Barrier and Epithelial Barrier for Oral Delivery of Insulin. Mol. Pharm. 17, 239–250 (2020). https://doi.org/10.1021/acs.molpharmaceut.9b00971
24. Goldiş, A., Dragomir, R., Mercioni, M.A., Goldiş, C., Sirca, D., Enătescu, I., Olariu, L., Belei, O.: Personalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Multi-Omics and Interventional Approach. Microorganisms. 13, 1047 (2025). https://doi.org/10.3390/microorganisms13051047

25. Gebrayel, P., Nicco, C., Al Khodor, S., Bilinski, J., Caselli, E., Comelli, E.M., Egert, M., Giaroni, C., Karpinski, T.M., Loniewski, I., Mulak, A., Reygner, J., Samczuk, P., Serino, M., Sikora, M., Terranegra, A., Ufnal, M., Villeger, R., Pichon, C., Konturek, P., Edeas, M.: Microbiota medicine: towards clinical revolution. J. Transl. Med. 20, 111 (2022). https://doi.org/10.1186/s12967-022-03296-9
26. Gao, Y., Liu, Y., Ma, T., Liang, Q., Sun, J., Wu, X., Song, Y., Nie, H., Huang, J., Mu, G.: Fermented Dairy Products as Precision Modulators of Gut Microbiota and Host Health: Mechanistic Insights, Clinical Evidence, and Future Directions. Foods. 14, 1946 (2025). https://doi.org/10.3390/foods14111946
27. Ji, J., Jin, W., Liu, S., Jiao, Z., Li, X.: Probiotics, prebiotics, and postbiotics in health and disease. MedComm. 4, e420 (2023). https://doi.org/10.1002/mco2.420
28. Smolinska, S., Popescu, F.-D., Zemelka-Wiacek, M.: A Review of the Influence of Prebiotics, Probiotics, Synbiotics, and Postbiotics on the Human Gut Microbiome and Intestinal Integrity. J. Clin. Med. 14, 3673 (2025). https://doi.org/10.3390/jcm14113673
29. Xie, M.-X., Ye, J.-L., Chen, H.-Q., Huang, S.-Y., Cheng, J., Li, H.-B., Pang, J.-Z., Zhang, X.-G., Zhu, H.-L.: Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics and Postbiotics for the Prevention and Management of Type 2 Diabetes Mellitus. Food Rev. Int. 41, 2203–2218 (2025). https://doi.org/10.1080/87559129.2025.2532726
30. Yilmaz, Y.: Postbiotics as Antiinflammatory and Immune-Modulating Bioactive Compounds in Metabolic Dysfunction-Associated Steatotic Liver Disease. Mol. Nutr. Food Res. 68, 2400754 (2024). https://doi.org/10.1002/mnfr.202400754
31. Silva, Y.P., Bernardi, A., Frozza, R.L.: The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front. Endocrinol. 11, 25 (2020). https://doi.org/10.3389/fendo.2020.00025
32. Abbasi, E., Khodadadi, I.: High-fat diet may increase the risk of insulin resistance by inducing dysbiosis. Metab. Open. 27, 100381 (2025). https://doi.org/10.1016/j.metop.2025.100381
33. Hong, L., Lee, S.-M., Kim, W.-S., Choi, Y.-J., Oh, S.-H., Li, Y.-L., Choi, S.-H., Chung, D.H., Jung, E., Kang, S.-K., Cho, C.-S.: Synbiotics Containing Nanoprebiotics: A Novel Therapeutic Strategy to Restore Gut Dysbiosis. Front. Microbiol. 12, (2021). https://doi.org/10.3389/fmicb.2021.715241
34. Muttiah, B., Hanafiah, A.: Gut Microbiota and Cardiovascular Diseases: Unraveling the Role of Dysbiosis and Microbial Metabolites. Int. J. Mol. Sci. 26, 4264 (2025). https://doi.org/10.3390/ijms26094264
35. Qin, S., Liu, Y., Chen, Y., Hu, J., Xiao, W., Tang, X., Li, G., Lin, P., Pu, Q., Wu, Q., Zhou, C., Wang, B., Gao, P., Wang, Z., Yan, A., Nadeem, K., Xia, Z., Wu, M.: Engineered Bacteriophages Containing Anti-CRISPR Suppress Infection of Antibiotic-Resistant P. aeruginosa. Microbiol. Spectr. 10, e01602-22. https://doi.org/10.1128/spectrum.01602-22
36. McCready, A.R., Paczkowski, J.E., Cong, J.-P., Bassler, B.L.: An autoinducer-independent RhlR quorum-sensing receptor enables analysis of RhlR regulation. PLoS Pathog. 15, e1007820 (2019). https://doi.org/10.1371/journal.ppat.1007820
37. Wang, J., Jiao, H., Meng, J., Qiao, M., Du, H., He, M., Ming, K., Liu, J., Wang, D., Wu, Y.: Baicalin Inhibits Biofilm Formation and the Quorum-Sensing System by Regulating the MsrA Drug Efflux Pump in Staphylococcus saprophyticus. Front. Microbiol. 10, (2019). https://doi.org/10.3389/fmicb.2019.02800
38. Shah, T., Baloch, Z., Shah, Z., Cui, X., Xia, X.: The Intestinal Microbiota: Impacts of Antibiotics Therapy, Colonization Resistance, and Diseases. Int. J. Mol. Sci. 22, 6597 (2021). https://doi.org/10.3390/ijms22126597
39. Alkandahri, M.Y., Pamungkas, B.T., Oktoba, Z., Shafirany, M.Z., Sulastri, L., Arfania, M., Anggraeny, E.N., Pratiwi, A., Astuti, F.D., Indriyani, Dewi, S.Y., Hamidah, S.Z.: Hepatoprotective Effect of Kaempferol: A Review of the Dietary Sources, Bioavailability, Mechanisms of Action, and Safety. Adv. Pharmacol. Pharm. Sci. 2023, 1387665 (2023). https://doi.org/10.1155/2023/1387665
40. Awlqadr, F.H., Altemimi, A.B., Qadir, S.A., Hama Salih, T.A., Alkanan, Z.T., AlKaisy, Q.H., Mohammed, O.A., Hesarinejad, M.A.: Emerging trends in nano-sensors: A new frontier in food safety and quality assurance. Heliyon. 11, e41181 (2025). https://doi.org/10.1016/j.heliyon.2024.e41181
41. Bilia, A.R., Bergonzi, M.C.: The G115 standardized ginseng extract: an example for safety, efficacy, and quality of an herbal medicine. J. Ginseng Res. 44, 179–193 (2020). https://doi.org/10.1016/j.jgr.2019.06.003
42. Shemtov, S.J., Emani, R., Bielska, O., Covarrubias, A.J., Verdin, E., Andersen, J.K., Winer, D.A.: The intestinal immune system and gut barrier function in obesity and aging. FEBS J. 290, 4163–4186 (2023). https://doi.org/10.1111/febs.16558
43. Alum, E.U., Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
44. Bhattacharjee, S., de Haan, L.H., Evers, N.M., Jiang, X., Marcelis, A.T., Zuilhof, H., Rietjens, I.M., Alink, G.M.: Role of surface charge and oxidative stress in cytotoxicity of organic monolayer-coated silicon nanoparticles towards macrophage NR8383 cells. Part. Fibre Toxicol. 7, 25 (2010). https://doi.org/10.1186/1743-8977-7-25

45. Lasola, J.J.M., Cottingham, A.L., Scotland, B.L., Truong, N., Hong, C.C., Shapiro, P., Pearson, R.M.: Immunomodulatory Nanoparticles Mitigate Macrophage Inflammation via Inhibition of PAMP Interactions and Lactate-Mediated Functional Reprogramming of NF-κB and p38 MAPK. Pharmaceutics. 13, 1841 (2021). https://doi.org/10.3390/pharmaceutics13111841
46. Melhem, H., Regan-Komito, D., Niess, J.H.: Mucins Dynamics in Physiological and Pathological Conditions. Int. J. Mol. Sci. 22, 13642 (2021). https://doi.org/10.3390/ijms222413642
47. Huang, W., Metlakunta, A., Dedousis, N., Zhang, P., Sipula, I., Dube, J.J., Scott, D.K., O'Doherty, R.M.: Depletion of Liver Kupffer Cells Prevents the Development of Diet-Induced Hepatic Steatosis and Insulin Resistance. Diabetes. 59, 347–357 (2010). https://doi.org/10.2337/db09-0016
48. Wang, S., Zhang, L., Wang, M., Yin, X., Dong, X., Wu, X., Li, W., Xu, W., Mao, X.: Engineered upconversion nanoparticles for breast cancer theranostics. Theranostics. 15, 8259–8319 (2025). https://doi.org/10.7150/thno.116153
49. Amidon, S., Brown, J.E., Dave, V.S.: Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches. AAPS PharmSciTech. 16, 731–741 (2015). https://doi.org/10.1208/s12249-015-0350-9
50. Chen, J.-C., Chen, C.-M., Aoh, Y., Cheng, Y.-K., Lu, M.-K., Tsai, C.-H.: Immediate Motor Control Enhancement via Pallidothalamic Tract (PTT) Circuit Ablation: A Dual-Target MR-Guided Focused Ultrasound Approach for Tremor-Dominant Parkinson's Disease. Eur. J. Neurol. 32, e70345 (2025). https://doi.org/10.1111/ene.70345
51. Liu, X., Naomi, S.S.M., Sharon, W.L., Russell, E.J.: The Applications of Focused Ultrasound (FUS) in Alzheimer's Disease Treatment: A Systematic Review on Both Animal and Human Studies. Aging Dis. 12, 1977–2002 (2021). https://doi.org/10.14336/AD.2021.0510
52. Hu, C., Jia, W.: Multi-omics profiling: the way toward precision medicine in metabolic diseases. J. Mol. Cell Biol. 13, 576–593 (2021). https://doi.org/10.1093/jmcb/mjab051
53. Ayakdaş, G., Ağagündüz, D.: Microbiota-accessible carbohydrates (MACs) as novel gut microbiome modulators in noncommunicable diseases. Heliyon. 9, e19888 (2023). https://doi.org/10.1016/j.heliyon.2023.e19888
54. Belančić, A.: Gut microbiome dysbiosis and endotoxemia - Additional pathophysiological explanation for increased COVID-19 severity in obesity. Obes. Med. 20, 100302 (2020). https://doi.org/10.1016/j.obmed.2020.100302
55. Afzal, O., Altamimi, A.S.A., Nadeem, M.S., Alzarea, S.I., Almalki, W.H., Tariq, A., Mubeen, B., Murtaza, B.N., Iftikhar, S., Riaz, N., Kazmi, I.: Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomaterials. 12, 4494 (2022). https://doi.org/10.3390/nano12244494
56. Obeagu EI, Alum EU, Obeagu GU, Ugwu OP. Prostate Cancer: Review on Risk Factors. Eurasian Experiment Journal of Public Health(EEJPH). 2023;4(1):4-7.
57. Ugwu OP, Amasiorah VI. The effects of crude ethanol root extract and fractions of sphenocentrum jollyanum on the lipid profile of streptozotocininduced diabetic wistar albino rats. IDOSR Journal of Biology, Chemistry And Pharmacy. 2020;5(1):36-46.
58. Igwenyi IO, Nchi PO, Okechukwu UP, Igwenyi IP, Obasi DC, Edwin N, Uraku AJ, Ze AC. Nutritional potential of Azadirachta indica seeds. Indo American Journal of Pharmaceutical Sciences. 2017 Feb 1;4(2):477-82.
59. Offor CE, Okaka AN, Ogbugo SO, Egwu CO, Ugwu PC. Effects of ethanol leaf extract of Pterocarpus santalinoides on haemoglobin, packed cell volume and platelets. IOSR-JNHS 2015; 4: 108. 2015;112:93.
60. Obeagu EI, Alum EU, Ugwu OPC. Hepcidin: The gatekeeper of iron in malaria resistance. Newport Int J Res Med Sci. 2023;4(2):1–8. doi:10.59298/NIJRMS/2023/10.1.1400.
61. Offor CE, Agidi JU, Egwu CO, Ezeani N, Okechukwu PCU. Vitamin and mineral contents of Gongronema latifolium leaves. World J Med Sci. 2015;12(2):189–91.
62. Ogbanshi ME, Agbafor KN, Ominyi CM, Okechukwu PCU, Nwali BU, Ali FU. Changes in reproductive functions of adult male rats administered water and salt samples from Okposi and Uburu Nigerian salt lakes. Am Eurasian J Toxicol Sci. 2015;7(2):55–62.
63. Okechukwu PCU, Offor CE, Ibiam UA, Ezugwu AL, Uraku AJ, Igwe CN, Okon MB. The effect of ethanol extract of Jatropha curcas on renal markers of chloroform intoxicated albino Wistar rats. Eur J Biol Sci. 2015;7(1):21–5. doi:10.5829/idosi.ejbs.2015.7.01.1106.
64. Offor CE, Aja PC, Ugwu O, Agbafo KN. The effects of ethanol leaf-extract of Gmelina arborea on total protein and albumin concentrations in albino rats. Glob. J. Environ. Res. 2015;9(1):1-4.
65. Alum E, Ugwu PC, Egba S, Uti D, Alum B. Extension, KP: Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR Scientific Research. 11, 16–22 (2024) [Internet]. 2013
66. Onyeze RC, Udeh SM, Okwor JC, Ugwu OP. Isolation and characterization of bacteria that are associated with the production and spoilage of ogi (akamu). International Journal of Pharma Medcine and Biological Sciences. 2013;2(3):79-85.
67. Alum EU, Obeagu EI, Ugwu OP-C. Enhancing quality water, good sanitation, and proper hygiene is the panacea to diarrhea control and the attainment of some related sustainable development goals: A review. Medicine (Baltimore). 2024 Sep 20;103(38):e39578. doi:10.1097/MD.0000000000039578.

68. Alum EU, Uti DE, Obeagu EI, Ugwu OPC, Alum BN. Cancer's psychosocial aspects: impact on patient outcomes. Elite J Med. 2024;2(6):32–42.
69. Alum EU, Ugwu OP. Nutritional Strategies for Rheumatoid Arthritis: Exploring Pathways to Better Management. INOSR Scientific Research. 2023;10(1):18-26.
70. Alum EU, Mathias CD, Ugwu OP, Aja PM, Obeagu EI, Uti DE, Okon MB. Phytochemical composition of Datura stramonium ethanol leaf and seed extracts: A comparative study. IAA Journal of Biological Sciences. 2023;10(1):118-25.
71. Ugwu Okechukwu PC, Amasiorah VI. Review on Health Implications. Benefits and Biochemistry of Alcohol Intoxication, INOSR Experimental Sciences. 2020;6(1):62-74.
72. PC UO, Amasiorah VI. Review on Health Implications, Benefits and Biochemistry of Alcohol Intoxication. INOSR Experimental Sciences. 2020;6(1):62-74.
73. Okechukwu P, Ossai D, Tukur G, Eze O, Ekwueme OC. Bacteriuria and urinary schistosomiasis in primary school children in rural communities in Enugu State, Nigeria. Pan African Medical Journal. 2014;18:15.
74. Odo Christian E, Nwodo Okwesili FC, Joshua Parker E, Ugwu Okechukwu PC, Okonkwo CC. Acute Toxicity Investigation And Anti-Diarrhoeal Effect Of The Chloroform-Methanol Extract Of Seed Of Persea Americana. Journal of Pharmacy Research. 2013;6(2):331-5.
75. Alum EU, Uti DE, Ugwu OPC, Obeagu EI, Alum BN. Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment. Discov Onc. 2025;16:646. doi:10.1007/s12672-025-02352-2.
76. Alum EU, Ugwu OPC, Egba SI, Uti DE, Alum BN. Climate variability and malaria transmission: unraveling the complex relationship. INOSR Sci Res. 2024;11(2):16–22. doi:10.59298/INOSRSR/2024/1.1.21622.
77. Ugwu CN, Okon MB, Ugwu OP. The Effects of Freezing on the Nutritional Composition of Fish. INOSR Experimental Sciences. 2024;13(1):61-5.
78. Alum EU, Ugwu OP, Obeagu EI, Orji OU, Edwin N, Okon MB. Religious Leaders as Advocates for Promoting Exclusive Breastfeeding in East Africa. International Journal of Innovative and Applied Research. 2023;11(12):10-5.
79. Obeagu EI, Obeagu GU, Alum EU, Ugwu OP. Comprehensive Review of Antiretroviral Therapy Effects on Red Blood Cells in HIV Patients. INOSR Experimental Sciences. 2023;12(3):63-72.
80. Onyeze RC, Onah GT, Onwukwe CL, Ugwu OPC. Comparative effects of neem and lemongrass leaf extracts on Salmonella spp. World J Pharm Res. 2013;2(4):1177–1185.
81. Obeagu EI, Obeagu GU, Alum EU, Ugwu OP. Understanding the Impact of HIV-Associated Bone Marrow Alterations on Erythropoiesis. INOSR Scientific Research. 2023;10(1):1-1.
82. Ugwu Okechukwu PC, Amasiorah VI. The In vitro Antioxidant Potentials of the Crude Ethanol Root Extract and Fractions of Sphenocentrum jollyanum. INOSR Applied Sciences 6 (1). 2020:125-33.
83. Ugwu Okechukwu PC, Onyeneke EC, Igwenyi IO, Aja PM, Ugwuoke KC, Okon Michael B, Onyeke SC. The Effects of Crude Ethanol Root Extract and Fractions of Sphenocentrum jollyanum on Liver and Kidney Function Parameters of StreptozotocinInduced Diabetic Wistar Aja PM, Udeh SM, Opajobi AO, Uzuegbu UE, Alum EU, Edwin N, Okechukwu UP. HEPATO-PROTECTIVE EFFECT OF AQUEOUS LEAF-EXTRACT OF TALINUM TRIANGULARE IN MONOSODIUM GLUTAMATE (MSG) INDUCED HEPATIC DAMAGE IN ALBINO RATS. Indo American Journal of Pharmaceutical Sciences. 2017 Feb 1;4(2):464-70.Albino Rats. IAA Journal of Scientific Research. 2018;4(1):75-90.
84. Offor C, Chukwu B, Igwenyi I, Ugwu OP, Aja P. Effect of Ethanol Leaf-Extract of Annona muricata on Serum Total Protein and Albumin Concentrations in Albino Rats. Academic Journal of Oral and Dental Medicine. 2015;2(1):5-7.
85. Chukwuezi Fabian O, Ugwu Okechukwu PC. Distribution of Mycobacterium bacilli in Onitsha Metropolis and its Relationship with HIV Infection. Pharmanest An International Journal of Advances in Pharmaceutical Sciences. 2013;4(5):902-6.
86. Uti DE, Alum EU, Atangwho IJ, Obeagu EI, Ugwu OPC. Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J Nanobiotechnol. 2025;23:336. doi:10.1186/s12951-025-03412-z.
87. Alum EU, Ugwu OPC. Artificial intelligence in personalized medicine: transforming diagnosis and treatment. Discov Appl Sci. 2025;7:193. doi:10.1007/s42452-025-06625-x.
88. Onyeze RC, Udeh SMC, Ani LC, Ugwu OPC. Microbiology of honey collected from three different locations in Enugu State, Nigeria. World J Pharm Res. 2013;2(4):1086–1095.
89. Enechi OC, Ibechem Augustine C, Ugwu Okechukwu PC. Distribution of Iodine and some goitrogens in two selected water bodies (Kalawa and Adaoka Rivers) in Enugu State, Nigeria. Exp. Int. J. Sci. Technol. 2013;12(1):748-61.
90. Alum EU, Obeagu EI, Ugwu OPC, Alum BN, Arinze ED, Ukaidi CUA. Exploring the differential impacts of intermittent fasting on men and women. Elite J Health Sci. 2024;2(5):37–44.
91. Edwin N, Obasi DC, Offor CE, Obasi JN, Ugwu OPC, Aja PM, Ogbanshi ME, Uraku AJ, Alum EU, Ali FU. Impact of soil physicochemical properties on mineral composition of cassava samples from Ikwo LGA of Ebonyi State, Nigeria. J Chem Soc Niger. 2022;47(6). doi:10.46602/jcsn.v47i6.821.

92. Ikezu UJM, Ajiwe VIE, Iloh EO, Okechukwu PCU. Phytochemical and atomic absorption spectroscopic analysis of root, stem and leaf extracts of Acanthus montanus. Middle East J Sci Res. 2014;21(6):875–878.
93. Udeozo IP, Akpaba ES, Ugwu OPC, Okoye NH, Umedum NL. Qualitative alkaloidal analyses of some selected Nigerian medicinal plants used in herbal treatment of diseases. Int J Life Sci Biotechnol Pharm Res. 2013;2(3):300–305.
94. Onyeze RC, Udeh SMC, Ilo PC, Ugwu OPC. Antibacterial evaluation of Moringa oleifera leaf extract on selected bacterial pathogens (Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa). World J Pharm Res. 2013;2(4):1065–1077.
95. Alum EU, Obasi DC, Abba JN, Aniokete UC, Okoroh PN, Ugwu OPC, Uti DE. Endogenous plant signals and human health: molecular mechanisms, ecological functions, and therapeutic prospects. Biochem Biophys Rep. 2025;43:102114. doi:10.1016/j.bbrep.2025.102114.
96. Mezieobi KC, Alum EU, Ugwu OPC, Uti DE, Alum BN, Egba SI, Ewah CM. Economic burden of malaria on developing countries: a mini review. Parasite Epidemiol Control. 2025;30:e00435. doi:10.1016/j.parepi.2025.e00435
97. Alum EU, Nwuruku OA, Ugwu OPC, Uti DE, Alum BN, Edwin N. Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomed Plus. 2025;5(3):100828. doi:10.1016/j.phyplu.2025.100828.
98. Nyamboga TO, Ugwu OPC, Ugwu JN, Alum EU, Eze VHU, Ugwu CN, Ejemot-Nwadiaro RI. Biotechnological innovations in soil health management: a systematic review of integrating microbiome engineering, bioinformatics, and sustainable practices. Cogent Food Agric. 2025;11(1):2519811. doi:10.1080/23311932.2025.2519811.
99. Madu CV, Alum EU, Aloh HE, Ugwu OPC, Obeagu EI, Uti DE, Egba SI, Ukaidi CUA, Alum NB. The price of progress: assessing the financial costs of HIV/AIDS management in East Africa. Medicine (Baltimore). 2025;104(18):e42300. doi:10.1097/MD.0000000000042300.
100. Ugwu OPC, Anyaegbunam CN, Uzochukwu MN, Onohuean H. Harnessing plant metabolic pathways for innovative diabetes management: unlocking the therapeutic potential of medicinal plants. Plant Signal Behav. 2025;20(1):2486076. doi:10.1080/15592324.2025.2486076.
101 Ogbodo JO, Egba SI, Ikechukwu GC, Paul PC, Mba JO, Ugwu OPC, Ezike TC. Volatile organic compound–drug receptor interactions: a potential tool for drug design in the search for remedies for increasing toxic occupational exposure. Processes. 2025;13(1):154. doi:10.3390/pr13010154.
102. Nwite MO, Agwu SC, Afiukwa CA, Ugwu OPC. Comprehensive phenotypic assessment of rice diseases in cultivated farms within Okpuitumo Community, Ikwo Local Government Area, Ebonyi State: implications for sustainable rice crop management. Newport Int J Biol Appl Sci. 2023;4(1):26–31. doi:10.59298/NIJBAS/2023/1.4.11111.
103. Uraku AJ, Okechukwu PCU, Nzubechukwu E. Preliminary phytochemical screening of Spilanthes uliginosa, Ocimum basilicum, Hyptis spicigera and Cymbopogon citratus leaf extracts and haematological changes of mice infected with malaria parasite. Am Eurasian J Sci Res. 2015;10(1):12–17.
104. Enechi OC, Ogochukwu BO, Okechukwu PCU. Effect of fermentation on biochemical properties of maize (Zea mays L.). World Appl Sci J. 2014;31(5):724–729.
105. Onyeze RC, Onah GT, Nwadi NO, Ugwu OPC. Bacteriological examination of abattoir with reference to Escherichia coli and Staphylococcus species. World J Pharm Res. 2013;2(4):1154–1163.
106. Ogugua VN, Anaduaka EG, Chijioke C, Egba SI, Ugwu OPC. Effects of storage on auto-oxidation levels of selected alcoholic and non-alcoholic beverages in Nsukka town, Enugu State of Nigeria. World J Pharm Res. 2013;2(4):758–764.
107. Ogugua VN, Anaduaka EG, Chijioke C, Egba SI, Ugwu OPC. Effects of storage on auto-oxidation levels ofselected alcoholic and non-alcoholic beverages in Nsukka town, Enugu State of Nigeria. World J Pharm Res. 2013;2(4):758–764.
108. Omeh YS, Ijioma VU, Ugwu OPC, Enechi OC. Characterisation and fatty acid profile of Cucurbita pepo seed oil. World J Pharm Pharm Sci. 2013;2(3):825–832.
109 Omeh YS, Ugwu OPC, Enechi OC. The effect of feeding Mucuna oil on the lipid profile and creatine kinase enzyme of albino rats. World J Pharm Pharm Sci. 2013;2(3):802–813.
110.Enechi OC, Obiora EN, Okechukwu PU. Chromatographic Identification and the Effect of the Alkaloidal Extract of Buccholzia coriaceae Seeds on the Body Weights and Relative Liver Weights of Mice. Advances in Biological Research. 2013;7(5):188-93.
111. Adachukwu P, Ifunanya C. International Journal of Research and Reviews in Pharmacy and Applied science www. ijrrpas. com.

**CITE AS: Muhindo Anitah (2026). Engineering Nanoparticles to Modulate Gut Microbiota in Obesity-Induced Insulin Resistance. IAA Journal of Scientific Research 13(1):102-110. https://doi.org/10.59298/IAAJSR/2026/131102110**